$146M Deal In Aggrenox Pay-For-Delay MDL Gets Initial OK

Law360, San Francisco (September 20, 2017, 2:16 PM EDT) -- A Connecticut federal judge on Tuesday preliminarily approved a $146 million settlement between direct purchasers and pharmaceutical companies over the drugmakers' alleged role in a scheme to block generic alternatives to the stroke-prevention drug Aggrenox from coming on the market.

U.S. District Judge Stefan R. Underhill found that the deal, under which each direct buyer will receive a pro rata share of the settlement, is fair, reasonable and adequate for the purposes of preliminary approval.

"The court finds that the proposed settlement ... as set forth in the settlement agreement, was arrived at by arm's-length negotiations by highly experienced counsel after...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!